Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.62 |
| ▸ | TTR | P02766 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12884286 | 0.94 | GRM5 (0.65) | GRM5KCNH2TTRNPC1RAB9A | |
| SCHEMBL15422868 | 0.85 | TTR (0.68) | GRM5KCNH2TTRNPC1RAB9A | |
| SCHEMBL21858065 | 0.85 | GRM5 (0.56) | GRM5KCNH2TTRNPC1RAB9A | |
| SCHEMBL484570 | 0.85 | GRM5 (0.56) | GRM5KCNH2TTRNPC1RAB9A | |
| SCHEMBL12884290 | 0.85 | TTR (0.62) | GRM5KCNH2TTRCYP1A2ALDH1A1 | |
| SCHEMBL15877809 | 0.83 | GRM5 (0.59) | GRM5KCNH2TTRCYP1A2CYP3A4 | |
| SCHEMBL15877543 | 0.82 | GRM5 (0.56) | GRM5KCNH2TTRNCF1NOS2 | |
| SCHEMBL2808633 | 0.81 | TTR (0.55) | GRM5KCNH2TTRNPC1RAB9A | |
| SCHEMBL2808776 | 0.81 | TTR (0.62) | GRM5KCNH2TTRNPC1RAB9A | |
| SCHEMBL4713149 | 0.81 | TTR (0.55) | GRM5KCNH2TTRCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946431-B2 | 2-(substituted ethynyl)quinoline derivatives as mGLUr5 antagonists | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-02-03 | — | — | US | claimed |
| US-20140206876-A1 | 2-(Substituted ethynyl)quinoline Derivatives as mGLUr5 Antagonists | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-07-24 | — | — | US | claimed |
| US-9879004-B2 | Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-9815788-B2 | Anti-angiogenic compounds | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2017-11-14 | — | — | US | disclosed |
| US-9815788-B2 | Anti-angiogenic compounds | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2017-11-14 | — | — | US | disclosed |
| US-20170050930-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-02-23 | — | — | US | disclosed |
| US-20170050930-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-02-23 | — | — | US | disclosed |
| US-9388138-B2 | Anti-angiogenic compounds | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-07-12 | — | — | US | disclosed |
| US-9388138-B2 | Anti-angiogenic compounds | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-07-12 | — | — | US | disclosed |
| US-20150376182-A1 | Substituted Acetylene Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2015-12-31 | — | — | US | disclosed |
| EP-2953933-A1 | SUBSTITUTED ACETYLENE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | Merck Patent GmbH (DE) | 2015-12-16 | — | — | EP | disclosed |
| US-20150218100-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-08-06 | — | — | US | disclosed |
| US-8946431-B2 | 2-(substituted ethynyl)quinoline derivatives as mGLUr5 antagonists | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-02-03 | — | — | US | disclosed |
| WO-2014121883-A1 | SUBSTITUTED ACETYLENE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | WO | disclosed |
| US-20140206876-A1 | 2-(Substituted ethynyl)quinoline Derivatives as mGLUr5 Antagonists | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-07-24 | — | — | US | disclosed |
| EP-1032393-B1 | QUINOLINE-CONTAINING ALPHA-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON INC (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1032393-A4 | QUINOLINE-CONTAINING ALPHA-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON INC (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1032393-A1 | QUINOLINE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| US-6083944-A | ENZYME INHIBITORS; TREATMENT OF VARIOUS DEBILITATING DISORDERS | CEPHALON, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| WO-1999017775-A1 | QUINOLINE-CONTAINING α-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON INC. (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376182-A1 | Substituted Acetylene Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | GRM4, GRIA4, GRIK4 | GRM5 6/4885KCNH2 2236/4885TTR 4837/4885 |
| US-20170050930-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, VHL | GRM5 3709/4885KCNH2 4753/4885TTR 1646/4885 |
| US-20150218100-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, VHL | GRM5 3709/4885KCNH2 4753/4885TTR 1646/4885 |
| US-20140206876-A1 | 2-(Substituted ethynyl)quinoline Derivatives as mGLUr5 Antagonists | GRM5, GRIK5, GRIA4 | GRM5 1/4885KCNH2 1318/4885TTR 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.